US경제·CNBC Business RSS· 번역 중
AI가 열심히 번역 중이에요 🤖
곧 한글 번역본을 제공해드릴게요. 잠시만 기다려주세요!
Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
2026.07.23 22:52
AI 감성 분석
롱 (매수 신호)롱 73%숏 27%
리들리의 차세대 비만 치료제 파이프라인에 대한 긍정적인 임상 결과가 장기적인 성장 기대치를 높여 주가에 긍정적인 영향을 미칠 것입니다.
핵심 요약
There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of its obesity portfolio.
There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of its obesity portfolio.
Original Article
Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of its obesity portfolio.